Franklin Street Advisors Inc. NC Invests $346,000 in Insulet Corporation $PODD

Franklin Street Advisors Inc. NC purchased a new position in shares of Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, HoldingsChannel.com reports. The fund purchased 1,100 shares of the medical instruments supplier’s stock, valued at approximately $346,000.

Several other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after acquiring an additional 178,976 shares during the period. American Century Companies Inc. raised its holdings in Insulet by 34.8% in the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after buying an additional 297,734 shares during the period. Groupama Asset Managment raised its holdings in Insulet by 0.4% in the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock valued at $276,728,000 after buying an additional 3,759 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Insulet by 4.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier’s stock valued at $177,096,000 after buying an additional 27,408 shares during the period. Finally, Federated Hermes Inc. raised its holdings in Insulet by 23.4% in the 1st quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier’s stock valued at $166,198,000 after buying an additional 120,197 shares during the period.

Insulet Stock Performance

Shares of Insulet stock opened at $309.11 on Friday. Insulet Corporation has a one year low of $225.37 and a one year high of $353.50. The company has a market cap of $21.76 billion, a PE ratio of 93.95, a P/E/G ratio of 2.59 and a beta of 1.40. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The business has a 50-day simple moving average of $321.34 and a 200-day simple moving average of $298.54.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same period in the previous year, the company posted $0.55 earnings per share. The business’s revenue for the quarter was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Morgan Stanley restated an “overweight” rating on shares of Insulet in a report on Thursday, August 7th. Citigroup restated a “buy” rating on shares of Insulet in a report on Tuesday, July 8th. The Goldman Sachs Group reduced their price objective on shares of Insulet from $399.00 to $375.00 and set a “buy” rating on the stock in a report on Wednesday. Wells Fargo & Company boosted their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an “overweight” rating in a research note on Friday, August 8th. Finally, Truist Financial initiated coverage on shares of Insulet in a research note on Monday, June 16th. They set a “buy” rating and a $365.00 price target on the stock. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $345.47.

Insider Transactions at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.